Literature DB >> 30697879

Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.

Tamara Lund1, Carsten Sand1, Robert Gniadecki1, Simon F Thomsen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30697879     DOI： 10.1111/dth.12846

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study.

Authors:  Matteo Megna; Luigi Fornaro; Luca Potestio; Maria Antonietta Luciano; Mariateresa Nocerino; Mario Delfino; Maria Guarino; Gabriella Fabbrocini; Elisa Camela
Journal:  Psoriasis (Auckl)       Date:  2022-07-09

2.  Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.

Authors:  Witold Owczarek; Irena Walecka; Agnieszka Nowakowska; Piotr Ciechanowicz; Adam Reich; Aleksandra Lesiak; Ewa Borkowska; Andrzej Śliwczyñski; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2021-08-16       Impact factor: 1.664
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.